The Effect of Metformin on Androgen Production in Diabetic Women with Non-classic Congenital Adrenal Hyperplasia

 

 Buy Article Permissions and Reprints

Abstract

Non-classic congenital adrenal hyperplasia (NC-CAH), one of the most common genetic disorders, is often associated with the clinical features of hyperandrogenism. This study included 19 women with recently diagnosed and previously untreated type 2 diabetes, 8 of whom suffered from NC-CAH, treated with metformin (2.55–3.0 g daily). Glucose homeostasis markers, plasma lipids, as well as plasma levels of 17-hydroxyprogesterone, androgens and gonadotropins were assessed at baseline and after 6 months of therapy. In both groups of patients, metformin reduced fasting plasma glucose, insulin resistance, triglycerides and glycated hemoglobin. Moreover, in patients with NC-CAH, but not in women with normal adrenal function, metformin decreased plasma levels of 17-hydroxyprogesterone, total and free testosterone, androstenedione and dehydroepiandrosterone sulphate. The obtained results suggest that metformin partially normalizes androgen production in symptomatic patients with NC-CAH.

• References

• 1 American Diabetes Association . Standards of medical care in diabetes – 2013. Diabetes Care 2013; 36 (Suppl. 01) S11-S66
  CrossrefPubMedGoogle Scholar
• 2 Genuth S. The UKPDS and its global impact. Diabet Med 2008; 25 (Suppl. 02) 57-62
  CrossrefPubMedGoogle Scholar
• 3 Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
  CrossrefPubMedGoogle Scholar
• 4 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5: 157-167
  CrossrefPubMedGoogle Scholar
• 5 Mahmood K, Naeem M, Rahimnajjad NA. Metformin: the hidden chronicles of a magic drug. Eur J Intern Med 2013; 24: 20-26
  CrossrefPubMedGoogle Scholar
• 6 Rachoń D. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2012; 120: 205-209
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Krysiak R, Okopień B, Gdula-Dymek A et al. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006; 58: 614-625
  PubMedGoogle Scholar
• 8 Loverro G, Lorusso F, De Pergola G et al. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002; 16: 217-224
  CrossrefPubMedGoogle Scholar
• 9 Diamanti-Kandarakis E, Kouli C, Tsianateli T et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269-274
  CrossrefPubMedGoogle Scholar
• 10 Barba M, Schünemann HJ, Sperati F et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2009; 70: 661-670
  CrossrefPubMedGoogle Scholar
• 11 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011; 96: 3493-3501
  CrossrefPubMedGoogle Scholar
• 12 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94: 4938-4945
  CrossrefPubMedGoogle Scholar
• 13 Auchus RJ. Congenital adrenal hyperplasia in adults. Curr Opin Endocrinol Diabetes Obes 2010; 17: 210-216
  CrossrefPubMedGoogle Scholar
• 14 Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord 2009; 10: 77-82
  CrossrefPubMedGoogle Scholar
• 15 Moran C, Azziz R. 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med 2003; 21: 295-300
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 456-461
  CrossrefPubMedGoogle Scholar
• 17 Sathyapalan T, Kilpatrick ES, Coady AM et al. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94: 103-108
  CrossrefPubMedGoogle Scholar
• 18 Kaya C, Pabuccu R, Cengiz SD et al. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Exp Clin Endocrinol Diabetes 2010; 118: 161-166
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Krysiak R, Okopien B. The effect of simvastatin treatment on plasma steroid levels in females with non-classic congenital adrenal hyperplasia. Exp Clin Endocrinol Diabetes 2013; 121: 643-646
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Mapas-Dimaya AC, Agdere L, Bahtiyar G et al. Metformin-responsive classic salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a case report. Endocr Pract 2008; 14: 889-891
  CrossrefPubMedGoogle Scholar
• 21 Miller WL. Steroidogenic enzymes. Endocr Dev 2008; 13: 1-18
  PubMedGoogle Scholar
• 22 Mansfield R, Galea R, Brincat M et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003; 79: 956-962
  CrossrefPubMedGoogle Scholar
• 23 Tosca L, Solnais P, Ferré P et al. Metformin-induced stimulation of adenosine 5′ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod 2006; 75: 342-351
  CrossrefPubMedGoogle Scholar